TRACK-LVO: Triage of Patients With Acute Ischemic Stroke Due to Large Vessel Occlusions

Sponsor
Tianjin Huanhu Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05659160
Collaborator
(none)
8,000
1
132
60.6

Study Details

Study Description

Brief Summary

The aim of this study is to establish an academic, real-world, single-center, observational registry of consecutive patients hospitalized with acute ischemic stroke (AIS) due to large vessel occlusions (LVO), treated with either endovascular therapy (EVT) or best medical management (BMM).

Condition or Disease Intervention/Treatment Phase
  • Procedure: Endovascular Therapy

Detailed Description

Stroke is a major threat to public health and is exacerbating socioeconomic development. It is the leading cause of mortality among residents in China. Large vessel occlusion (LVO) is a predictor of unfavorable outcomes and can account for up to 52% of patients with acute ischemic stroke (AIS). The definition of LVO and its optimal screening imaging modalities remain controversial. In this registry, the investigators defined LVO as an occlusion of the intracranial ICA with or without the involvement of the terminal bifurcation, M1 and/or M2 segment of the MCA, A1 and/or A2 segment of the ACA, VA, BA, or P1 and/or P2 segment of the PCA.

TRACK-LVO is an academic, real-world, single-center, observational registry, in which consecutive patients hospitalized with AIS due to LVO will be treated with either EVT or BMM. Baseline information and clinical follow-up information at 90 days from stroke onset are collected. The key baseline items in this registration for both EVT and BMM groups include basic demographic profiles, past medical history, NIHSS score, treatment with intravenous alteplase, type of stroke onset, time from stroke onset to admission/imaging, imaging characteristics such as volume of ischemic core and occlusion site, and treatment-related complications. Additional information collected in EVT groups includes details of EVT procedure and angiographic images.

The investigators enrolled patients with LVO screened under different imaging modalities to further reveal the optimal imaging modalities in the detection of LVO. The investigators also tend to compare the prognosis of AIS patients with LVO receiving endovascular therapy and best medical management respectively.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
8000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Triage of Patients With Acute Ischemic Stroke Due to Large Vessel Occlusions (TRACK-LVO): an Imaging-based Patient Registry Study
Actual Study Start Date :
Jan 1, 2018
Anticipated Primary Completion Date :
Dec 31, 2028
Anticipated Study Completion Date :
Dec 31, 2028

Arms and Interventions

Arm Intervention/Treatment
Endovascular therapy

Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombus aspiration, others, or combination methods.

Procedure: Endovascular Therapy
Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging. Endovascular therapy includes any one or more of the following: Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.

Best medical management

Patients enrolled in this group received the best medical management.

Outcome Measures

Primary Outcome Measures

  1. Modified ranking scale (mRS) at 90 days [90 days]

    The scale runs from 0-6, running from perfect health without symptoms to death.

  2. Mortality within 90 days [90 days]

    mortality of any causes

Secondary Outcome Measures

  1. National Institutes of Health Stroke Scale (NIHSS) scores at 90 days [90 days]

    The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.

  2. Occurrence of periprocedural complications [14 days postoperatively]

    Periprocedural complications include any intracranial hemorrhage, cerebral edema, brain herniation and pneumonia.

  3. ASPECT (Alberta Stroke Program Early CT score) [Day 0]

    ASPECTS is a 10-point quantitative topographic CT scan score used in patients with middle cerebral artery (MCA) stroke.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patient admitted from Jan. 1st 2018 to Jan. 1st 2028;

  2. Age ≥ 18;

  3. Ischemic stroke confirmed by head CT or MRI;

  4. Large vessel occlusion confirmed by head CTA or MRA: intracranial internal carotid artery (ICA), middle cerebral artery (MCA M1/M2), anterior cerebral artery (ACA A1/A2), basilar artery (BA), vertebral artery (VA), and posterior cerebral artery (PCA P1/P2);

  5. Patients receiving either endovascular therapy or best medical treatment;

Exclusion Criteria:
  • None

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tianjin Huanhu Hospital Tianjin Tianjin China 300222

Sponsors and Collaborators

  • Tianjin Huanhu Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ming Wei, Chief Physician, Tianjin Huanhu Hospital
ClinicalTrials.gov Identifier:
NCT05659160
Other Study ID Numbers:
  • TJHH-2022-WM12
First Posted:
Dec 21, 2022
Last Update Posted:
Dec 22, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ming Wei, Chief Physician, Tianjin Huanhu Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 22, 2022